At 48 h after treatment, CCC-003 significantly increased the number of Annexin V-positive SH-SY5Y and Kelly cells in a dose-dependent manner, while the mismatch polyamide had little influence on the viability of ALK-mutated neuroblastoma cells (Fig 5A and 5B and S6 Fig). The gene discussed is ALK; the disease is neuroblastoma.